Cerebral Microvascular Disease and TMS/Spravato Safety
Cerebral microvascular disease is NOT a contraindication for TMS, but IS an absolute contraindication for Spravato (esketamine nasal spray).
Spravato (Esketamine): Absolute Contraindication
The FDA label explicitly contraindicates Spravato in patients with aneurysmal vascular disease (including intracranial vessels) or arteriovenous malformation, as well as those with a history of intracerebral hemorrhage 1. While the label does not specifically mention "cerebral microvascular disease" by name, this condition represents a spectrum of small vessel pathology that increases risk for intracerebral hemorrhage and may involve arteriovenous abnormalities. Given that:
- Cerebral microvascular disease increases hemorrhagic stroke risk
- The FDA contraindication includes intracranial vascular disease and history of intracerebral hemorrhage
- Esketamine causes acute blood pressure elevations (a known adverse effect that could precipitate hemorrhage in vulnerable vasculature)
You should not prescribe Spravato to patients with known cerebral microvascular disease. The risk of precipitating intracerebral hemorrhage in already-compromised small vessels outweighs potential benefits, particularly when alternative treatments for treatment-resistant depression exist 2, 3.
TMS: Generally Safe, But Requires Careful Assessment
In contrast, TMS does not have cerebral microvascular disease listed as a contraindication in established guidelines 4. The primary contraindications for TMS include 4, 5, 6:
Absolute contraindications:
- Cardiac pacemakers or other implanted electrical devices near the stimulating coil
- Intracranial clips or metal objects
Relative contraindications:
- Epilepsy or seizure history
- Recent cerebrovascular accident (stroke)
- Known intracortical pathology
- Medications that lower seizure threshold
- Pregnancy
Key Consideration for TMS in Microvascular Disease
The critical nuance is "recent cerebrovascular accident" as a relative contraindication 4. If the patient with cerebral microvascular disease has had a recent stroke (particularly within 3 months), this warrants extreme caution due to seizure induction risk. However, chronic, stable microvascular disease without recent acute events does not automatically preclude TMS use 5, 6.
Before proceeding with TMS in a patient with cerebral microvascular disease, you should:
- Obtain recent neuroimaging (MRI preferred) to assess for acute/subacute infarcts or hemorrhage
- Ensure no stroke within the past 3 months
- Verify no structural lesions that could serve as epileptogenic foci
- Confirm patient is not on medications that significantly lower seizure threshold
- Consider starting with lower intensity protocols and monitoring closely for adverse effects
Clinical Algorithm
For Spravato:
- Known cerebral microvascular disease → Do NOT prescribe
- Consider alternative treatments: standard TMS, ECT, or other pharmacologic options 2, 7
For TMS:
- Cerebral microvascular disease + recent stroke (<3 months) → Defer TMS until stable
- Cerebral microvascular disease + remote/no stroke history + no structural lesions → May proceed with TMS after thorough neuroimaging review and informed consent discussion
- Monitor closely during initial sessions for any neurological changes 5, 6, 8
Common Pitfall
Do not assume that because both are "brain treatments," they carry the same vascular risks. Spravato's mechanism involves acute sympathetic activation and blood pressure elevation, directly stressing already-compromised cerebral vasculature 1. TMS uses magnetic field induction without systemic hemodynamic effects, making it fundamentally safer in vascular disease (though seizure risk from cortical irritability remains a consideration) 4, 5.
The evidence strongly supports that TMS has a favorable safety profile even in populations with various neurological conditions 5, 8, whereas Spravato's FDA contraindications are explicit and non-negotiable regarding intracranial vascular pathology 1.